Innovative vaccine production technologies: The evolution and value of vaccine production technologies

  title={Innovative vaccine production technologies: The evolution and value of vaccine production technologies},
  author={Kyungdong Bae and Junyoul Choi and Yangsuk Jang and Sang-Jeom Ahn and Byung-Gi Hur},
  journal={Archives of Pharmacal Research},
This review paper provides an overview of innovative technologies designed to produce bacterial, viral, recombinant subunit, and polysaccharide vaccines, as well as combination vaccines. Advances in this field are illustrated by vaccines against DTP (diphtheria-tetanus-pertussis), influenza, hepatitis B (HepB) and typhoid fever. In addition, technological trends regarding antigens, adjuvants, and preservatives in vaccines are discussed. The progress achieved in vaccine production technologies… 
Vaccine process technology
The evolution of vaccine process technology has occurred in parallel to the remarkable growth in the development of therapeutic proteins as products; therefore, recent vaccine innovations can leverage the progress made in the broader biotechnology industry.
The Evolution and Value of Diphtheria Vaccine
Innovative technologies and approaches with the potential to overcome limitations of conventional formalin-inactivated toxoid vaccines have been discussed in this paper, which target improvements in vaccine quality, safety, stability and consistency, ease of use and/or thermal stability.
Vaccine Types
Most non-live vaccines generally require additional doses ("boosters") to maintain long-term protective immunity, and some of these vaccines are associated with life-long immunity.
Immunomodulators as adjuvants for vaccines and antimicrobial therapy
A highly effective strategy for combating infectious diseases is to enhance host defenses using immunomodulators, either preventatively, through vaccination, or therapeutically. The effectiveness of
Vaccines in Veterinary Medicine: A Brief Review of History and Technology
  • S. McVeyJishu Shi
  • Medicine
    Veterinary Clinics of North America: Small Animal Practice
  • 2010
Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.
A simple method for improving the potency and efficacy of a recombinant subunit antigen by its immobilization on nickel-chelating nanolipoprotein particles (NiNLPs), which are membrane mimetic nanoparticles that provide a delivery and presentation platform amenable to binding any recombinantSubunit immunogens featuring a polyhistidine tag.
Expression of peptide nanoparticles containing a porcine reproductive and respiratory syndrome (PRRS) virus epitope in plants
It was shown by transmission electron microscopy that the chimeric protein nanoparticles can be efficiently synthesized and self-assembled inside plant cells and are efficiently transcribed by real-time polymerase chain reaction (PCR).
Vaccine Production in Africa: A Feasible Business Model for Capacity Building and Sustainable New Vaccine Introduction
Investment in vaccine production in Africa could be triggered and in which way it could be affordable to most African governments or investors with a smart 5 years tangible implementation plan, marketing agreements within existing regional collaborations and with a strong political will.
Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus
Data indicate that a replikin peptide vaccine, specifically made against the H5N1 Black Duck/NC/674-964/06 isolate, and administered three times to the upper respiratory tract, was capable of protecting chickens from infection and from shedding of the homologous virus.
A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection
Bacterial surface lipoproteins are emerging as attractive vaccine candidates due to their biological importance and the feasibility of their large-scale production for vaccine manufacturing. The


Development and production aspects of a recombinant yeast-derived hepatitis B vaccine.
Selection of potent immunological adjuvants for vaccine construction.
Baculovirus-expressed influenza vaccine
  • A. SafdarM. Cox
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 2007
The conclusion that the insect cell–baculovirus production technology is a modern solution for rapid viral or parasitic antigen production is made and that this technology is particularly suitable for influenza where annual adjustment of the vaccine is required.
Development and clinical application of new polyvalent combined paediatric vaccines.
A review of the current status of enteric vaccines.
An engineered live oral cholera vaccine, strain CVD 103-HgR, has been shown in extensive clinical trials to be well tolerated by children and adults in less developed countries and highly immunogenic following administration of just a single oral dose; a large-scale field trial of the efficacy of this vaccine is underway.
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.
The current status of typhoid vaccine development and clinical trials with typhoid vaccines.
Parenteral purified Vi polysaccharide of S. typhi (single 25 mcg dose) was safe and immunogenic and provided 64-72% protection (for at least 17-21 months) in controlled field trials in Nepal and South Africa.
Progress in vaccines against typhoid fever.
Parenteral purified Vi polysaccharide of S. typhi was safe and immunogenic and provided 64%-72% protection (for at least 17-21 months) in controlled field trials in Nepal and South Africa.
The effectiveness of whole-cell pertussis vaccines.
  • S. Plotkin
  • Biology
    Developments in biological standardization
  • 1997
The acellular pertussis vaccine efficacy trials revealed significant facts concerning the whole cell vaccines used as controls, and it is faced with the fact that a well-prepared whole-cell vaccine still provides the best protection against pertussi.
New acellular pertussis-containing paediatric combined vaccines.